Login to Your Account



Infinity Shifts Focus in Wake Of Phase II Hedgehog Failure

By Trista Morrison
Staff Writer

Monday, January 30, 2012
Shares of Infinity Pharmaceuticals Inc. dropped 40 percent Friday on news that the biotech is stopping development of Hedgehog inhibitor saridegib (IPI-926) in pancreatic cancer after interim data from a Phase II trial showed better survival in the placebo arm.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription